Business Development
FXT is looking for partnerships to accelerate the development of its proprietary technologies and the growth of the company.
FXT is open to partner its lead BSCI small molecule FX125L for development beyond clinical proof of concept, other BSCI small molecules for development as topical anti-inflammatory products and its GAEL technology platform for the identification of novel small molecules with unique pharmacologic profiles.FXT is interested in licensing-in assets from both academia and other companies, with a demonstrated preclinical proof of concept in the area of inflammation.
To learn more about partnering opportunities with FXT, please contact Konstantinos Efthymiopoulos, Chief Executive Officer (info@funxionaltherapeutics.com) for further information.